| 货号 | ICH5025G1 |
|---|
| 品牌 | IchorBio |
|---|
| 描述 |
Blinatumomab - Human IgG1 (Clone AMG103) ( ICH5025G1) is a Human, clone L2K-07 and HD37 (Human IgG1 Kappa) antibody targeting CD3 x CD19. Reactive with Human. Validated for FA, FC, IP, WB.
Highlights
- ●Low Endotoxin — Suitable for in vivo and functional studies.
- ●High Purity — Minimal background for reliable results.
- ●Validated Applications — Tested in FA, FC, IP, WB.
|
|---|
| 种属反应性 | Human |
|---|
| 应用 | FA, FC, IP, WB |
|---|
| 宿主 | Human |
|---|
| 克隆类型 | Monoclonal |
|---|
| 同种型 | Human IgG1 Kappa |
|---|
| 克隆号 | L2K-07 and HD37 |
|---|
| 免疫原 | CD19 murine parental clone is HD37 and CD3E murine parental clone is L2K-07. |
|---|
| 经测试应用 | FA, FC, IP, WB |
|---|
| 靶标 | CD3 x CD19 |
|---|
| 特异性 | Human CD19 on B cells and CD3E on T cells. |
|---|
| 内毒素水平 | ≤ 1.0 EU/mg as determined by the LAL method |
|---|
| 纯度 | ≥95% by SDS Page, ≥95% monomer by analytical SEC |
|---|
| 纯化方式 | This monoclonal antibody was purified using Protein A |
|---|
| Accession号 | P07766/ P15391 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
This product is supplied as a sterile, aseptically packaged formulation in 0.01 M phosphate-buffered saline (150 mM NaCl), pH 7.2–7.4, with no carrier protein, potassium, calcium, or preservatives added. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 运输 | Blue Ice |
|---|
| 稳定性和存储 | This product may be stored sterile as received at 2–8°C for up to one month. For longer-term storage, aseptically aliquot into working volumes without diluting and store at -80°C. Avoid repeated freeze-thaw cycles. |
|---|
| 规格 | Size: 1mg; Aggregation: As with many antibody preparations, some lots may develop precipitate over time due to the inherent biochemical properties of the protein. If this occurs, precipitate can be removed by aseptic centrifugation and/or filtration prior to use. |
|---|
| 别名 | CD3E: T-cell surface antigen T3/Leu-4 epsilon chain, T3E; CD19: B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12; CD19: B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12 |
|---|
| 背景 | This product is a recombinant fusion protein combining the anti-CD19/anti-CD3 single-chain variable fragments (scFvs) of clone AMG103 with a human IgG1 Fc domain. The added Fc domain extends serum half-life via FcRn recycling and introduces Fc-mediated effector function (e.g., ADCC/CDC) not present in the native molecule. It also simplifies laboratory handling, allowing Protein A/G purification and detection with standard anti-Fc reagents. By contrast, Blinatumomab BIosimilar (ICH5025) is a bispecific T-cell engager (BiTE) that redirects CD3+ T cells to CD19+ B cells by binding both antigens simultaneously via the same tandem scFvs, but lacks an Fc region. Because it lacks an Fc domain, native blinatumomab has a very short serum half-life and requires continuous intravenous infusion in clinical use. As such, this IgG1 Fc-fusion version is intended as a research tool for studying the impact of Fc engineering on bispecific antibody pharmacokinetics and effector function, not as an equivalent to blinatumomab biosimilar. CD19 is expressed on the surface of nearly all B cells, both healthy and malignant, with the notable exceptions of hematopoietic stem cells and plasma cells. Its expression remains highly conserved across B-cell malignancies, making it a reliable marker for this lineage. CD3E, by contrast, is a surface glycoprotein found on T cells. |
|---|
| Note | For research only |
|---|
| Isotype Control | ICH2254 |
|---|
